Gilvetmab

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Gilvetmab
www.ebi.ac.uk

  • endostar pd 1 inhibitor
  • gilvetmab
  • Gilvetmab
  • gilvetmab [INN]
  • GILVETMAB [USAN]
  • gilvetmab inn
  • gilvetmab usan
  • immunoglobulin gb anti canis familiaris programmed cell death protein 1 canis familiaris mus musculus monoclonal heavy chain disulfide with canis familiaris mus musculus light chain dimer
  • IMMUNOGLOBULIN GB, ANTI-(CANIS FAMILIARIS PROGRAMMED CELL DEATH PROTEIN 1) (CANIS FAMILIARIS-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISULFIDE WITH CANIS FAMILIARIS-MUS MUSCULUS LIGHT CHAIN, DIMER
  • pd 1 gilvetmab
  • pd 1 inhibitor gilvetmab
  • Pd-1 (gilvetmab)
  • PD-1 inhibitor
  • PD-1 Inhibitor
  • Pd-1 inhibitor (gilvetmab)
  • PD-1inhibitor
  • pd1
  • PD1

CAS registry numbers
  • 1808081-43-7
ChEMBL ID
CHEMBL3990007
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 949NG8376D

Patents
0
Designations
1
First in class
No
Fast track
No
Breakthrough designation
No
Orphan designation
No
Priority review
No
Orphan exclusivity
No
Accelerated approval
No

Drug name stem
-mab

  • Condition identifier
    EFO_0000181
    Highest recorded phase
    2
  • Condition identifier
    EFO_0005537
  • Condition identifier
    MONDO_0001056
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0002691
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0003060
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0004952
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005105
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005575
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0007256
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0009831
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0010150
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0040679
    Highest recorded phase
    2

  • Event
    abdominal infection
    Reports
    3
    Reporting signal score
    13.1537
  • Event
    abdominal pain
    Reports
    15
    Reporting signal score
    21.1216
  • Event
    adrenal insufficiency
    Reports
    4
    Reporting signal score
    11.2464
  • Event
    alanine aminotransferase increased
    Reports
    20
    Reporting signal score
    51.4244
  • Event
    amylase increased
    Reports
    2
    Reporting signal score
    6.17235
  • Event
    anaemia
    Reports
    32
    Reporting signal score
    69.7599
  • Event
    ascites
    Reports
    5
    Reporting signal score
    11.0281
  • Event
    aspartate aminotransferase increased
    Reports
    20
    Reporting signal score
    53.7244
  • Event
    blood bilirubin increased
    Reports
    8
    Reporting signal score
    20.2336
  • Event
    blood creatinine increased
    Reports
    5
    Reporting signal score
    6.80073
  • Event
    cardiotoxicity
    Reports
    3
    Reporting signal score
    8.31973
  • Event
    cerebral radiation injury
    Reports
    1
    Reporting signal score
    8.35679
  • Event
    constipation
    Reports
    11
    Reporting signal score
    15.3768
  • Event
    cortisol abnormal
    Reports
    1
    Reporting signal score
    6.37632
  • Event
    decreased appetite
    Reports
    25
    Reporting signal score
    56.394
  • Event
    dermatitis
    Reports
    5
    Reporting signal score
    14.1823
  • Event
    diarrhoea
    Reports
    35
    Reporting signal score
    51.3806
  • Event
    endocrine toxicity
    Reports
    1
    Reporting signal score
    6.97075
  • Event
    fatigue
    Reports
    29
    Reporting signal score
    35.0731
  • Event
    gastrointestinal disorder
    Reports
    6
    Reporting signal score
    10.5574
  • Event
    gastrointestinal haemorrhage
    Reports
    8
    Reporting signal score
    13.0745
  • Event
    gastrointestinal toxicity
    Reports
    3
    Reporting signal score
    10.0581
  • Event
    gingival bleeding
    Reports
    3
    Reporting signal score
    7.58019
  • Event
    haematotoxicity
    Reports
    5
    Reporting signal score
    15.5255
  • Event
    hepatic function abnormal
    Reports
    14
    Reporting signal score
    40.3843

And 45 more, listed on the interactive page.

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSSASTTAPSVFPLAPSCGSTSGSTVALACLVSGYFPEPVTVSWNSGSLTSGVHTFPSVLQSSGLYSLSSMVTVPSSRWPSETFTCNVAHPASKTKVDKPVPKRENGRVPRPPDCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEVTCVVVALDPEDPEVQISWFVDGKQMQTAKTQPREEQFAGTYRVVSVLPIGHQDWLKGKQFTCKVNNKALPSPIERTISKARGQAHQPSVYVLPPSREELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQESLSHSPGK
  • Component
    Disulfide bridges location
    Sequence
    22-96$22''-96$23'-88'$23'''-88'''$134'-194'$134'''-194'''$135-214'$135''-214'''$147-203$147''-203''$232-232''$235-235''$267-327$267''-327''$373-433$373''-433''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIKRNDAQPAVYLFQPSPDQLHTGSASVVCLLNSFYPKDINVKWKVDGVIQDTGIQESVTEQDSKDSTYSLSSTLTMSSTEYLSHELYSCEITHKSLPSTLIKSFQRSECQRVD

Related records

Trials (266)

In development for (1)

Other linked conditions (1)